Sophie Schmitz and Joanna Fernandes discuss bluebird bio’s innovative gene therapy Zynteglo and its withdrawal from the European market. Sophie and Joanna will be looking at the fall of Zynteglo from two sides: from a company perspective and from the perspective of the EU environment.
Presenter: Georgie Rack, Communication Executive
Contributors: Sophie Schmitz, Managing Partner and Joanna Fernandes, Senior Consultant
Producer: Operations team
